Cabergoline
Impaired Glucose Tolerance in Obese
Columbia UniversitySmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Impaired Glucose Tolerance in Obese cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DULAGLUTIDE University of Pennsylvania | Phase 4 | BBB |
NEPENTHE Washington University School of Medicine | Phase 4 | BB |
DULAGLUTIDE The University of Texas Health Science Center, Houston | Phase 4 | BB |
Bxcl501 Pontificia Universidad Catolica de Chile | Phase 4 | BB |
CYANOCOBALAMINUM The University of Texas Health Science Center, Houston | Phase 4 | BB |
View all 16 →
Same molecule, other indications
Cabergoline is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →